Abstract TP215: Atrial Fibrillation and Flutter as a Cause of Stroke in an Unspecific Stroke Population. Stroke Subtypes in the Findaf Randomised Study
Introduction: The intensity of AF detection modalities in stroke patients has been modulated by the stroke subtype. Hence, most studies have been performed in so called cryptogenic stroke. However, it has never been proven that AF is more prevalent in cryptogenic stroke as compared to non-cryptogenic stroke. The Find-AF randomised trial (ISRCTN 46104198) is a randomised trial comparing prolonged Holter ECG monitoring (3x 10 day monitoring) and usual care in 400 patients with ischemic stroke. The primary results of Find-AF randomised will be submitted for presentation as a late breaking clinical trial to ISC 2016. In contrast to previous randomised trials (e. g. EMBRACE and CRYSTAL-AF), this trial will include all ischemic stroke patients, not only cryptogenic strokes.
Hypothesis: We hypothesized that the AF detection rate is independent from the stroke subtype according to the Trial of Org 10172 in Acute Stroke Treatment (TOAST), but is associated with clinical variables (e. g. age, NIHSS, prevalence of coronary artery disease).
Methods: 402 patients with ischemic stroke were recruited on certified stroke units within seven days after the index event. Stroke was classified by the Trial of Org 10172 in Acute Stroke Treatment (TOAST), dividing the patient collective into five subgroups according to the most likely stroke etiology.
Results: The following table presents a preliminary assessment of relevant baseline characteristics of 392 participants (full data set will be available upon abstract presentation.
In addition, all index strokes will be independently assessed by an adjudication committee, consisting of three neurologists. We will present AF detection rates in different stroke subtypes.
Conclusion: If our hypothesis is correct, future studies on AF detection in stroke patients should not be confined to stroke subtypes (e. g. cryptogenic or embolic stroke of unknown source), but rather include clinical parameters to increase the probability of finding AF.
Author Disclosures: A. Messerschmid: None. P.U. Heuschmann: None. N. Behnke: None. A. Schulte: None. F. Jürries: None. J. Liman: None. G.F. Hamann: None. P. Kermer: None. G. Gelbrich: None. M. Weber-Krüger: None. K. Gröschel: None. R. Wachter: Research Grant; Significant; Boehringer Ingelheim.
- © 2016 by American Heart Association, Inc.